STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Survodutide led to 13% weight loss after 76 weeks in a Phase 3 trial, versus 5% for placebo.
- Survodutide reduced liver fat by up to 63% versus 25% for placebo.
- Survodutide targets GLP‑1 and glucagon hormones, a dual agonist class.
- Survodutide appears less efficacious and less tolerable than existing obesity drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, raising doubts about its market competitiveness.
Why it matters: Boehringer Ingelheim's launch prospects dim as survodutide's 13% weight loss trails competitors, while its 63% liver‑fat reduction offers a distinct benefit for NAFLD patients in the U.S. market.
